rpoB mutations and their association with rifampicin resistance in clinical Staphylococcus epidermidis

Sofie Marie Edslev; Mia Aarris; Karen Leth Nielsen; Frederik B. Hertz; Thor Bech Johannesen; Camille Kolenda; Frederic Laurent; Emeli Mansson; Bo Soderquist; Marc Stegger

doi:10.1093/jac/dkaf035

Back

rpoB mutations and their association with rifampicin resistance in clinical Staphylococcus epidermidis

Journal article

Open access

rpoB mutations and their association with rifampicin resistance in clinical Staphylococcus epidermidis

Sofie Marie Edslev, Mia Aarris, Karen Leth Nielsen, Frederik B. Hertz, Thor Bech Johannesen, Camille Kolenda, Frederic Laurent, Emeli Mansson, Bo Soderquist and Marc Stegger

Journal of antimicrobial chemotherapy, Vol.80(4), pp.1067-1071

2025

DOI: https://doi.org/10.1093/jac/dkaf035

PMID: 39913260

Files and links (1)

pdf

Published8.57 MBDownload View

CC BY V4.0, Open Access

Abstract

Infectious Diseases

Life Sciences & Biomedicine

Microbiology

Pharmacology & Pharmacy

Science & Technology

Background Staphylococcus epidermidis is a ubiquitous member of the healthy skin and mucous microbiota but is also an opportunistic pathogen responsible for various infections, often treated with antibiotics like rifampicin. Resistance to rifampicin in S. epidermidis arises primarily through nonsynonymous mutations in the rpoB gene. Objectives To investigate the prevalence of rpoB mutations and their association with phenotypic rifampicin resistance in clinical S. epidermidis isolates from Denmark, France, and Sweden. Methods All clinical isolates (N = 942) were whole-genome sequenced to identify mutations in rpoB and subsequently linked to phenotypic rifampicin resistance based on antimicrobial susceptibility testing. Results A total of 64 (6.8%) isolates were resistant to rifampicin. They carried all mutational changes in the rifampicin resistance-determining region (RRDR). Among 12 identified nonsynonymous mutations, 11 were exclusively observed in resistant strains, including novel mutations not previously described in S. epidermidis. Conclusions This study highlights the diverse genetic variants of rpoB associated with rifampicin resistance in clinical S. epidermidis isolates, including novel mutations. The strong correlation between mutational changes in RRDR and phenotypic resistance reinforces the role of rpoB mutations as a primary mechanism of resistance in clinical isolates.

Details

Title: rpoB mutations and their association with rifampicin resistance in clinical Staphylococcus epidermidis
Authors/Creators: Sofie Marie Edslev - Statens Serum Institut
Mia Aarris - Statens Serum Institut
Karen Leth Nielsen - Copenhagen University Hospital
Frederik B. Hertz - Copenhagen University Hospital
Thor Bech Johannesen - Statens Serum Institut
Camille Kolenda - Hospices Civils de Lyon
Frederic Laurent - Hospices Civils de Lyon
Emeli Mansson - Mälardalen University
Bo Soderquist - Örebro University
Marc Stegger - Murdoch University
Publication Details: Journal of antimicrobial chemotherapy, Vol.80(4), pp.1067-1071
Publisher: Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Number of pages: 5
Grant note: OLL-502241 / Nyckelfonden at Orebro University Hospital
Identifiers: 991005743942607891
Murdoch Affiliation: Harry Butler Institute
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Metrics

26 File views/ downloads

11 Record Views

1 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.23 Antibiotics & Antimicrobials; 1.23.173 MRSA and VRE
Web Of Science research areas: Infectious Diseases; Microbiology; Pharmacology & Pharmacy
ESI research areas: Pharmacology & Toxicology